ArticleMedical oncology (Northwood, London, England)2025
Efficacy of curcumin-synthesized silver nanoparticles on MCF-7 breast cancer cells.
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The most common cancer in women worldwide and an important contributor to cancer-related death is breast cancer. Despite advances in treatment, current therapeutic methods remain insufficient, necessitating the development of innovative approaches. Nanotechnology, particularly silver nanoparticles (AgNPs), has emerged as a promising avenue in cancer therapy, offering the ability to target cancer cells through multiple mechanisms. In the current study, we aimed to investigate the anticancer potential of curcumin-biosynthesized AgNPs (C-AgNPs) and their molecular mechanisms on MCF-7 breast cancer cells. Cytotoxicity was assessed using the MTT assay, and the anti-migratory effect was determined through the scratch assay. The molecular mechanisms underlying these effects were investigated using RT-PCR to measure the expression levels of apoptotic-related genes, including P53, BAX, P21, and Bcl-2. Our results showed that C-AgNPs significantly inhibited MCF-7 cell migration. Moreover, gene expression analysis indicated the induction of apoptosis by upregulation of pro-apoptotic genes BAX and P53 and downregulation of Bcl-2. C-AgNPs demonstrated potent cytotoxic and anti-metastatic effects on MCF-7 cells, with the ability to induce apoptosis. C-AgNPs represent a promising candidate for the development of novel breast cancer therapies. However, further research is needed to address this effectiveness.
Indexed as
Identifiers
40522436What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.